OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)

CAPS Rating: 3 out of 5

Results 1 - 2 of 2

Recs

0
Member Avatar manirg (75.12) Submitted: 1/29/2014 12:07:04 PM : Outperform Start Price: $31.42 OMED Score: -47.98

High Risk but has Hugh Potential--5 to 10x. Backed by Celgene.

Recs

0
Member Avatar 5zillion (< 20) Submitted: 7/24/2013 3:40:08 PM : Outperform Start Price: $23.50 OMED Score: -32.80

Got in on tail end of this IPO and paid on the high end. Have to admit I have been biting my fingernails a little bit on this one. I do believe that with patience this one will pay off. With interest from GSK and Bayer I do believe they will be a good investment in due time.

Results 1 - 2 of 2

Featured Broker Partners


Advertisement